Intra-Cellular Therapies (ITCI) Misses Q2 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts ITCI Hot Sheet
Join SI Premium – FREE
Intra-Cellular Therapies (NASDAQ: ITCI) reported Q2 EPS of ($0.92), $0.16 worse than the analyst estimate of ($0.76). Revenue for the quarter came in at $55.6 million versus the consensus estimate of $49.08 million.
For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Tompkins Financial (TMP) Tops Q3 EPS by 5c
- AMTD Digital reports $1.2B in total assets, $42.4M profit
Create E-mail Alert Related Categories
EarningsRelated Entities
The Children's Investment Fund (TCI), EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
